These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. View from the Nation's Capital. Romansky MA J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408 [No Abstract] [Full Text] [Related]
3. Drug legislation. Drug companies divided. Gershon D Nature; 1990 May; 345(6270):6. PubMed ID: 2330052 [No Abstract] [Full Text] [Related]
4. View from the Nation's Capital. Romansky MA J Clin Psychopharmacol; 1983 Feb; 3(1):47-8. PubMed ID: 6680403 [No Abstract] [Full Text] [Related]
5. The Orphan Products Board of the Department of Health & Human Services. Crooks GM Prog Clin Biol Res; 1985; 197():19-23. PubMed ID: 4070294 [No Abstract] [Full Text] [Related]
6. Orphan products development and some methods for maximizing the usefulness of research on rare diseases. Finkel MJ Prog Clin Biol Res; 1985; 197():11-8. PubMed ID: 4070285 [No Abstract] [Full Text] [Related]
7. View from the Nation's Capital: the Orphan Drug Act--prospects and problems. Romansky MA J Clin Psychopharmacol; 1984 Aug; 4(4):230-2. PubMed ID: 6470200 [No Abstract] [Full Text] [Related]
8. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform. Clissold DB Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989 [No Abstract] [Full Text] [Related]
10. Adoption agent. Peota C Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583 [No Abstract] [Full Text] [Related]
11. Orphan drugs: the question of products liability. Scharf SF Am J Law Med; 1985; 10(4):491-513. PubMed ID: 3911776 [TBL] [Abstract][Full Text] [Related]
12. Orphan Drug Act on congressional agenda. von Oehsen WH Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123 [TBL] [Abstract][Full Text] [Related]
14. New products highlight ambiguity of orphan drug law. Reid B Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896 [No Abstract] [Full Text] [Related]
15. The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development. Engstrom LO Prog Clin Biol Res; 1985; 197():25-30. PubMed ID: 4070295 [No Abstract] [Full Text] [Related]
16. Introduction-Current activities and future goals of orphan disease agencies. Van Woert MH Prog Clin Biol Res; 1985; 197():3-6. PubMed ID: 4070296 [No Abstract] [Full Text] [Related]
17. The Orphan Drug Act: an engine of innovation? At what cost? Rohde DD Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720 [No Abstract] [Full Text] [Related]
18. Medical costs and the drug industry. Schwartz H Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744 [No Abstract] [Full Text] [Related]
19. Bush veto fuels orphan drug act uncertainties. Gershon D Nature; 1990 Nov; 348(6298):185. PubMed ID: 2234086 [No Abstract] [Full Text] [Related]
20. Drugs bill to rein in profits. Gershon D Nature; 1994 Mar; 368(6470):381. PubMed ID: 8133874 [No Abstract] [Full Text] [Related] [Next] [New Search]